On September 12, 2022 Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR platform to develop tolerogenic therapies for autoimmune diseases, enhance gene therapies and mitigate unwanted immune responses to biologics, reported that Company’s Management will participate in upcoming investor conferences in September (Press release, Selecta Biosciences, SEP 12, 2022, View Source [SID1234619400]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details on the conferences can be found below.

Cantor Fitzgerald’s Cell and Genetic Medicines Conference
Format: Panel presentation and one-on-one investor meetings, attending in-person
Panel Title: Ring Ring: Is That Large-Cap Pharma Calling? Importance of Established Partnerships in Place
Date: Thursday, September 15, 2022
Time: 8:00 a.m. ET
Location: New York, NY

To schedule a meeting with the Company, please contact your Cantor Fitzgerald representative.

Jefferies Cell and Genetic Medicine Summit
Format: Fireside chat and one-on-one investor meetings, attending in-person
Date: Friday, September 30, 2022
Time: 2:30 p.m. ET
Location: New York, NY

To schedule a meeting with the Company, please contact your Jefferies representative. The webcast of the fireside chat will be accessible in the Investors & Media section of the company’s website at www.selectabio.com.